Growing demand for mini fridges for beauty products and GLP-1 medication is reshaping homes, driven by the wellness industry and weight-loss drugs. This trend spans luxury to budget markets, despite dermatological skepticism for most skincare products.
Many insurance plans are dropping coverage for GLP-1 drugs like Zepbound and Wegovy for weight loss, leaving patients like Deborah Finley struggling to afford them. Experts suggest navigating coverage by checking fine print, filing appeals with doctor support, documenting care, seeking discounts, and being cautious with compounded versions.
A study of nearly 112,000 women found those taking GLP-1 drugs for diabetes or weight loss had a 30% lower chance of developing breast cancer. Researchers suggest metabolic effects and weight reduction may inhibit tumor growth.
